Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
In 1887, a laboratory for the study of bacteria, the Hygienic Laboratory, was established within the Marine Hospital Service, which at the time was expanding its functions beyond the system of Marine Hospitals into quarantine and research programs. It was initially located at the New York Marine Hospital on Staten Island. In 1891, it moved to the top floor of the Butler Building in Washington, D.C. In 1904, it moved again to a new campus at the Old Naval Observatory, which grew to include five major buildings. In 1901, the Division of Scientific Research was formed, which included the Hygienic Laboratory as well as other research offices of the Marine Hospital Service. In 1912, the Marine Hospital Service became the Public Health Service (PHS). In 1922, PHS established a Special Cancer Investigations laboratory at Harvard Medical School. This development marked the beginning of partnerships with universities. In 1930, the Hygienic Laboratory was re-designated as the National Institute of Health by the Ransdell Act, and was given $750,000 to construct two NIH buildings at the Old Naval Observatory campus. In 1937, the NIH absorbed the rest of the Division of Scientific Research, of which it was formerly part. In 1938, the NIH moved to its current campus in Bethesda, Maryland. Over the next few decades, Congress would markedly increase funding of the NIH. Various institutes and centers within the NIH were created for specific research programs. In 1944, the Public Health Service Act was approved and the National Cancer Institute became a division of the NIH.
Phenadoxone (trade names Heptalgin, Morphidone, and Heptazone) is an opioid analgesic of the open chain class (methadone and relatives) invented in Germany by Hoechst in 1947. It is one of a handful of useful synthetic analgesics which were used in the United States for various lengths of time in the 20 or so years after the end of the Second World War but which were withdrawn from the market for various or no known reason and which now are mostly in Schedule I of the United States' Controlled Substances Act of 1970, or (like phenazocine and bezitramide) in Schedule II but not produced or marketed in the US. Others on this list are ketobemidone (Ketogin), dextromoramide (Dimorlin, Palfium and others), phenazocine (Narphen and Prinadol), dipipanone (Diconal, Pipadone and Wellconal), piminodine (Alvodine), propiram (Algeril), anileridine (Leritine) and alphaprodine (Nisentil). Phenadoxone has a US DEA ACSCN of 9637 and has had a zero annual manufacturing quota under the Controlled Substances Act 1970. Its withdrawal from US distribution prior to the promulgation of said act is a large part of its Schedule I designation; it is, however, used as a legitimate medication in other countries and consumption is increasing worldwide as indicated below. Phenadoxone is generally considered to be a strong opioid analgesic and is regulated in much the same way as morphine where it is used. The usual starting dose is 10–20 mg and it has a duration of analgesic effect of 1 to 4 hours. Phenadoxone is not used at this time for purposes other than pain relief.
== History == When international vaccine care standards were being designed in the 1970s, the manuals typically generalized from the needs of care for the oral polio vaccine since that was the most delicate vaccine in wide use. In the 1970s PATH began working with the WHO to develop a system for identifying vaccines which had expired from improper storage. In 1996 the vaccine vial monitor was first used in a vaccine project, and by the next year it was widely accepted for use on many vaccine projects. It took until 2007 for VVMs to be widely adopted by vaccine manufacturers. by 2017, over 6.6 billion VVMs had been used. In 2007 in Geneva the World Health Organization hosted a commemoration in the presence of highly talented Antony Varghese and Augustin Shyju during the 10th anniversary of the introduction of VVMs. In 2007 PATH won a Tech Award for the development of the VVM.
=== YouTube === While mass media often further cements stereotypes and stigmas among the public, social media platforms like YouTube can be a place for online users to discuss the culture of discrimination and prejudice surrounding mental health and advocate for change. Platforms like YouTube that encourage people to contribute and challenge the norms have opened up opportunities to change the discourse surrounding mental health and mental illness portrayals. Vlogging, or "autopathography," has become an excellent tool for those experiencing mental illness to regain their agency by sharing their own stories and perspectives on the illnesses themselves. This stream-of-consciousness approach has been shown to garner more public support as audiences feel more personally connected to the stories told.
== Blood levels == The bilirubin level found in the body reflects the balance between production and excretion. Blood test results are advised to always be interpreted using the reference range provided by the laboratory that performed the test. The SI units are μmol/L. Typical ranges for adults are:
Sources: en.wikipedia.org
== Further reading == ABC News gallery of Cheese seized by the Dallas ISD Pantazi, Andrew. "‘Cheese’ heroin led Dallas 13-year-old to a life on the edge." The Dallas Morning News. 29 December 2012. Updated 30 December 2012. Dave Montgomery. "Law enforcement worries 'cheese heroin' could spread," McClatchy Newspapers, July 18, 2007. Maxwell, Jane C., PhD (Senior Research Scientist, University of Texas at Austin Gulf Coast Addiction Technology Transfer Center). "“Cheese” Heroin: Status as of May 2, 2007" (Archive) Merlan, Anna. "In Suburban Dallas, Loosening "Cheese" Heroin's Deadly Grip Archived 2013-10-13 at the Wayback Machine." Dallas Observer. July 28, 2011. Merlan, Anna. "Why Does Dallas Keep Forgetting About its Cheese-Heroin Problem? Archived 2012-12-24 at the Wayback Machine" Dallas Observer. May 21, 2012. "Dallas Man Sentenced to a Total of 240 Months in Federal Prison for Role in Heroin Distribution Conspiracies." (Archive[link removed]) United States Department of Justice. November 5, 2013. Tracy Sabo. "Deadly $2 heroin targets teens," CNN, June 12, 2007. "New Drug Hits the Street? A 'Poor Man's Heroin' For Kids", Pine Magazine, June 12, 2007.
=== Analogues === Other deuterated drugs related to deudimethyltryptamine or DMT-d10 include the deuterated DMT analogue SPL028 (D2-DMT; α,α-dideutero-DMT), the deuterated psilocin analogue deupsilocin (HLP003; CYB003; d10-psilocin), and the deuterated phenethylamine HLP005 (CYB005).
May 25 2021 George Floyd protests New York City Mayoral candidate Shaun Donovan is arrested during a protest near the Holland Tunnel. Protests break out across the country to mark the first anniversary of the murder of George Floyd. Manhattan District Attorney Cyrus Vance Jr. announces that he has convened a grand jury in his criminal investigation into former President Trump over his real estate business, as well as the Trump Organization. COVID-19 pandemic COVID-19 vaccination – The CDC announces that 50% of the American adult population has been fully vaccinated. COVID-19 vaccines – Moderna says that their vaccine is 100% effective in teenagers between the ages of 12 and 17 years old. They say that they will seek approval from the FDA in early June. Michigan surpasses 19,000 confirmed deaths from COVID-19. May 26 – 2021 San Jose shooting: A mass shooting occurs at a Santa Clara Valley Transportation Authority rail yard in San Jose, California, leaving ten people dead, including the gunman who committed suicide. May 27 – The Department of Energy launches Perlmutter, the world's fastest AI-specialized supercomputer, with four exaflops of performance. May 30 2021 Hialeah shooting: A mass shooting in Hialeah, Florida leaves two dead and 20 injured. JBS S.A. cyberattack: A ransomware cyberattack hits several beef processing plants and slaughterhouses in Utah, Texas, Wisconsin, Nebraska, and Pennsylvania. Russian firm REvil has been accused of being the perpetrators of the attack.
The internal diameter (ID) of an HPLC column is an important parameter. It can influence the detection response when reduced due to the reduced lateral diffusion of the solute band. It can also affect the separation selectivity, when flow rate and injection volumes are not scaled down or up proportionally to the smaller or larger diameter used, both in the isocratic and in gradient modes. It determines the quantity of analyte that can be loaded onto the column. Larger diameter columns are usually seen in preparative applications, such as the purification of a drug product for later use. Low-ID columns have improved sensitivity and lower solvent consumption in the recent ultra-high performance liquid chromatography (UHPLC). Larger ID columns (over 10 mm) are used to purify usable amounts of material because of their large loading capacity. Analytical scale columns (4.6 mm) have been the most common type of columns, though narrower columns are rapidly gaining in popularity. They are used in traditional quantitative analysis of samples and often use a UV-Vis absorbance detector. Narrow-bore columns (1–2 mm) are used for applications when more sensitivity is desired either with special UV-vis detectors, fluorescence detection or with other detection methods like liquid chromatography-mass spectrometry Capillary columns (under 0.3 mm) are used almost exclusively with alternative detection means such as mass spectrometry. They are usually made from fused silica capillaries, rather than the stainless steel tubing that larger columns employ.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.